Findings from St. Jude Children’s Research Hospital reveal that childhood cancer survivors with disadvantaged socio-demographic factors are over 7 times more likely to experience severe symptom burdens.
A tool created by St. Jude scientists may increase the safety of gene and cell therapy by finding safe places to add genes to human DNA.
St. Jude scientists have completed the largest study of families affected by Hodgkin lymphoma and identified novel variants linked to cancer predisposition.
St. Jude scientists sequenced the most childhood cancer samples from a single cancer type ever in a landmark study.
St. Jude Global and partners help Ukrainian children with cancer and blood disorders continue treatment, creating a model for responses to other crises.
St. Jude scientists created an LCK targeted PROTAC able to kill T-cell acute lymphoblastic leukemia cells.
St. Jude scientists developed a simple method to select for more effective cancer-destroying CAR T cells to treat T-ALL.
St. Jude scientists have created a proof-of-principle approach to improve engager T-cell therapy for difficult-to-treat acute myeloid leukemia.
Frank Fazio named president of Children's GMP and vice president of therapeutics production and quality at St. Jude
The Good Manufacturing Practices (GMP) facility produces highly specialized biopharmaceuticals and other biological products for the hospital’s clinics.
St. Jude scientists created a way to identify childhood cancer patients at diagnosis who are at the highest risk for developing severe obesity as adults.
Explore more research news
More Research News
Clinical Trials Alerts
Our e-newsletter for clinicians offers updates on St. Jude open clinical trials and research news.
Follow Us on Social Media
Connect with @stjuderesearch to keep up with our latest science and medical news. More about St. Jude social media.
Browse all scientific publications by St. Jude investigators.